1. US FDA. Accelerated approval. Published January 4, 2018. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval. Accessed 8 Dec 2021.
2. US FDA. Guidance for industry: expedited programs for serious conditions: drugs and biologics. Published May 2014. https://www.fda.gov/files/drugs/published/Expedited-Programs-for-Serious-Conditions-Drugs-and-Biologics.pdf. Accessed 23 Apr 2022.
3. Grossman LA. Choose your medicine: freedom of therapeutic choice in America. 1st ed. Oxford: Oxford University Press; 2021.
4. Fernandez Lynch H, Joffe S, McCoy MS. The limits of acceptable political influence over the FDA. Nat Med. 2021;27(2):188–90. https://doi.org/10.1038/s41591-020-01200-w.
5. Office of the Law Revision Counsel of the United States House of Representatives. Chapter 9. Federal Food, Drug, and Cosmetic Act. 21 USC §356. Expedited approval of drugs for serious or life-threatening diseases or conditions. https://uscode.house.gov/view.xhtml?req=(title:21%20section:356%20edition:prelim.) Accessed 24 Jan 2022.